BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11056328)

  • 1. How to manage the menopause following therapy for breast cancer. is raloxifene a safe alternative?
    Sismondi P; Biglia N; Roagna R; Ponzone R; Ambroggio S; Sgro L; Cozzarella M
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S74-6. PubMed ID: 11056328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D; Spencer CM
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective estrogen modulators in menopause.
    Gambacciani M
    Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A; Adachi JD
    Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue-selective estrogen complexes for postmenopausal women.
    Mirkin S; Komm BS
    Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for raloxifene use in daily clinical practice in the Swiss setting.
    Lippuner K; Buchard PA; De Geyter C; Imthurn B; Lamy O; Litschgi M; Luzuy F; Schiessl K; Stute P; Birkhäuser M
    Eur Spine J; 2012 Dec; 21(12):2407-17. PubMed ID: 22739699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective estrogen-receptor modulators.
    Cosman F
    Clin Geriatr Med; 2003 May; 19(2):371-9. PubMed ID: 12916292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on raloxifene to prevent endometrial-breast cancer.
    Goldstein SR
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S54-6. PubMed ID: 11056320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of raloxifene for treatment of menopause: a systematic review.
    Boyack M; Lookinland S; Chasson S
    J Am Acad Nurse Pract; 2002 Apr; 14(4):150-65. PubMed ID: 12001746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.
    Ko SS; Jordan VC
    Expert Opin Pharmacother; 2011 Mar; 12(4):657-74. PubMed ID: 21294695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacological review of selective oestrogen receptor modulators.
    Goldstein SR; Siddhanti S; Ciaccia AV; Plouffe L
    Hum Reprod Update; 2000; 6(3):212-24. PubMed ID: 10874566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of raloxifene and its clinical applications in osteoporosis.
    Maricic M; Gluck O
    Expert Opin Pharmacother; 2002 Jun; 3(6):767-75. PubMed ID: 12036416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond raloxifene for the prevention of osteoporosis and breast cancer.
    Jordan VC
    Br J Pharmacol; 2007 Jan; 150(1):3-4. PubMed ID: 17115068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist].
    Chmel R; Rob L; Strnad P
    Ceska Gynekol; 2002 Jul; 67(4):187-91. PubMed ID: 12373918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SERMs for the treatment and prevention of breast cancer.
    Swaby RF; Sharma CG; Jordan VC
    Rev Endocr Metab Disord; 2007 Sep; 8(3):229-39. PubMed ID: 17440819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
    Dickler MN; Norton L
    Ann N Y Acad Sci; 2001 Dec; 949():134-42. PubMed ID: 11795345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal effects of selective oestrogen receptor modulators (SERMs).
    Díez JL
    Hum Reprod Update; 2000; 6(3):255-8. PubMed ID: 10874570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene.
    Vogel VG
    Clin Interv Aging; 2008; 3(4):601-9. PubMed ID: 19281053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of international clinical trials with raloxifene].
    Agnusdei D; Liu-Léage S; Augendre-Ferrante B
    Ann Endocrinol (Paris); 1999 Sep; 60(3):242-6. PubMed ID: 10520416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.